Short Interest in Telix Pharmaceuticals Limited (NASDAQ:TLX) Decreases By 46.7%

Telix Pharmaceuticals Limited (NASDAQ:TLX) saw a significant decrease in short interest in the month of September. As of September 15th, there was short interest totaling 118,600 shares, a decrease of 46.7% from the August 31st total of 222,500 shares. Based on an average trading volume of 153,600 shares, the short-interest ratio is presently 0.8 days. Based on an average trading volume of 153,600 shares, the short-interest ratio is presently 0.8 days.

Institutional Trading of Telix Pharmaceuticals

Several hedge funds have recently modified their holdings of TLX. Pier Capital LLC acquired a new stake in shares of Telix Pharmaceuticals during the second quarter worth approximately $3,037,000. Russell Investments Group Ltd. acquired a new stake in shares of Telix Pharmaceuticals during the second quarter worth approximately $975,000. Jane Street Group LLC acquired a new stake in shares of Telix Pharmaceuticals during the second quarter worth approximately $564,000. ABC Arbitrage SA acquired a new stake in shares of Telix Pharmaceuticals during the first quarter worth approximately $451,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Telix Pharmaceuticals during the second quarter worth approximately $297,000.

Telix Pharmaceuticals Stock Up 0.6%

NASDAQ TLX opened at $10.28 on Friday. The company has a 50 day moving average of $10.82 and a 200-day moving average of $14.61. Telix Pharmaceuticals has a 1-year low of $8.93 and a 1-year high of $30.36.

Analysts Set New Price Targets

A number of research firms have issued reports on TLX. HC Wainwright decreased their price target on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating for the company in a report on Wednesday, September 10th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Saturday, September 27th. Wedbush reaffirmed an “outperform” rating and set a $22.00 price objective on shares of Telix Pharmaceuticals in a research report on Thursday, August 28th. William Blair reaffirmed an “outperform” rating on shares of Telix Pharmaceuticals in a research report on Wednesday, July 9th. Finally, UBS Group cut their price objective on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, September 23rd. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $21.00.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.